Associated Genetic Biomarkers
TG is altered in 20.36% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma, and breast neoplasm having the greatest prevalence of alterations .
The most common alteration in TG is TG Amplification (1.15%) .
TG status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains TG status as an inclusion criterion, 1 is phase 1/phase 2 (0 open).
The most frequent alteration to serve as an inclusion eligibility criterion is TG Expression .
Significance of TG in Diseases
Malignant Thyroid Gland Neoplasm +
TG is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TG status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1/phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.